At Zentiva, we provide health and wellbeing for all generations

We develop, produce, and deliver high-quality, affordable medicines to more than 100 million people in over 30 countries across Europe and beyond. Our team of 5,000 unique talents share a commitment to the people who depend on our medicines every day.

More information

Zentiva announces sale from Advent to GTCR

Zentiva, a leading European generics pharmaceutical company, Advent and GTCR – two leading global private equity investors – today announce the sale of Zentiva by Advent to GTCR.

More information

Zentiva at CPHI Frankfurt 2025: Innovation, Growth and Trusted Partnerships

Zentiva is pleased to announce its participation in CPHI Worldwide 2025, taking place from 28 to 30 October at Messe Frankfurt, Germany.

More information

Zentiva joins UN Target Gender Equality Accelerator

Gender equality is not only a fundamental human right – it is also a powerful driver of business success. As a pan-European company, we have both the responsibility and the opportunity to lead in advancing gender equality across the continent and beyond.

More information

Zentiva Climate Targets Officially Validated by the Science-Based Targets Initiative (SBTi)

Zentiva is proud to announce a significant step forward in its sustainability strategy with official validation of its targets by the Science Based Targets initiative (SBTi).

More information

Zentiva and Lupin Sign License and Supply Agreement for Biosimilar

Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for commercialization of Lupin!s biosimilar, TNF alpha inhibitor medicine, across multiple markets globally.

More information